LUCD•benzinga•
Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst
Summary
A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 11, 2025 by benzinga